Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This oropharyngeal spray is a fixed-dose combination developed by Geiser Pharma for the symptomatic relief of throat infections and associated pain. It contains three active ingredients: two antiseptic agents (amylmetacresol and 2,4-dichlorobenzyl alcohol) and one local anesthetic (lidocaine). Amylmetacresol and 2,4-dichlorobenzyl alcohol provide broad-spectrum antiseptic activity against bacteria and viruses associated with mouth and throat infections. Lidocaine acts rapidly as a local anesthetic by blocking voltage-gated sodium channels, providing significant relief from severe sore throat and pharyngeal pain. The formulation is typically delivered as a 20ml peppermint-flavored topical spray and is approved for use in several markets as an over-the-counter (OTC) or pharmacy-dispensed healthcare product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amylmetacresol + 2,4-dichlorobenzyl alcohol + lidocaine.